Results 41 to 50 of about 27,891 (280)

Montelukast promotes mitochondrial biogenesis via CREB/PGC-1α in human bronchial epithelial cells

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Bronchial epithelial mitochondrial dysfunction including impaired mitochondrial biogenesis has been linked with the initiation and development of bronchial asthma.
Huan Wang   +4 more
doaj   +1 more source

Protective effect of leukotriene receptor antagonist montelukast on smoking-induced lung injury in Wistar rats. [PDF]

open access: yes, 2003
Increased activation of alveolar macrophage, neutrophil and mast cell has been proven in cigarette smoking (CS)-related lung disorders (CSLD). An increased production of cysteinyl-leukotrienes (LTs), which are mediators secreted from the mentioned cells,
Coskun, Senol   +3 more
core   +1 more source

Integrating evidence for managing asthma in patients who smoke [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Bjermer, Leif   +3 more
core   +1 more source

Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2)

open access: yesBioengineered, 2021
Montelukast is a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist widely used to suppress the inflammatory response in asthma and allergic rhinitis.
Zongwei Li, Jianming Wang, Yumin Ma
semanticscholar   +1 more source

Real-world research and its importance in respiratory medicine [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Brusselle, Guy   +4 more
core   +5 more sources

Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19

open access: yesPharmacology, 2021
Background: The coronavirus disease-19 (COVID-19) pandemic is a serious devastating disease and has posed a global health emergency. So far, there is not any specific therapy approved till date to control the clinical symptoms of the disease.
M. Dey, R. Singh
semanticscholar   +1 more source

The examination of the nephroprotective effect of montelukast sodium and N-acetylcysteine ın renal ıschemia with dimercaptosuccinic acid imaging in a placebo-controlled rat model [PDF]

open access: yesActa Cirúrgica Brasileira, 2020
Purpose To determine the nephroprotective effect of NAC and Montelukast Sodium administration against the development of renal damage associated with long warm renal ischemia.
Arif Aydin   +9 more
doaj   +1 more source

Churg-Strauss and Montelukast

open access: yesInternational Journal of Immunopathology and Pharmacology, 2011
Churg-Strauss syndrome (CSS) is a systemic small vessel vasculitis involving lungs, skin, heart, gastrointestinal tract and peripheral nerves. We report the case of a 36-year-old woman with a necrotic lesion on the left foot of two months duration, associated with hypereosinophilia, patchy lung infiltrates, cardiac damage and a mononeuritis.
CARLESIMO, Marta   +4 more
openaire   +3 more sources

Montelukast does not increase the risk of attention-deficit/hyperactivity disorder in pediatric asthma patients: A nationwide population-based matched cohort study

open access: yesJournal of the Formosan Medical Association, 2021
Background: Attention-deficit/hyperactivity disorder (ADHD) has been linked to pediatric asthma patients treated with montelukast. This study is the first to use a nationwide health insurance research database (NHIRD) to study whether asthmatic children ...
Po-Yu Huang   +6 more
doaj  

Home - About - Disclaimer - Privacy